Latest Information Update: 10 Dec 2007
At a glance
- Originator Elan Corporation; QLT USA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 30 May 2001 Preclinical development for Emesis in USA (Transmucosal)